Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.15897 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lupus erythematosus and dermatomyositis.
Clin Dermatol
December 2024
Department of Dermatology, Yale School of Medicine, New Haven, CT. Electronic address:
Dr. Irwin Braverman, a luminary in our field of dermatology, united his love of internal medicine with dermatology to pioneer our understanding of the cutaneous manifestations of systemic disease. His meticulous documentation of physical examination findings in his book Skin Signs of Systemic Disease became fundamental to the training of dermatologists worldwide for decades.
View Article and Find Full Text PDFRegional ischaemic immune myopathy: unraveling a rare subtype of dermatomyopathy.
BMJ Case Rep
December 2024
Rheumatology, Western Health, Melbourne, Victoria, Australia.
Regional ischaemic immune myopathy (RIIM) is a subtype of dermatomyopathy which has distinct histopathology features of regional muscle fibre necrosis and regeneration. This case report aims to provide an in-depth exploration of RIIM, emphasising its clinical features and the crucial role of muscle biopsy as a diagnostic investigation, as well as the potential role of immunomodulatory therapies.
View Article and Find Full Text PDFOccult ovarian adenocarcinoma manifesting as dermatomyositis.
BMJ Case Rep
December 2024
Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
A woman in her 60s presented with erythematous lesions predominantly over the joints. After evaluation by dermatology and rheumatology, she was diagnosed with dermatomyositis and initiated on oral steroids and immunosuppressants. She was subsequently referred to gynaecology services for further evaluation of possible malignancies.
View Article and Find Full Text PDFPrognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicenter cohort study of 73 patients.
Rheumatology (Oxford)
November 2024
Service de Dermatologie et Allergologie, Hôpital Tenon, Sorbonne Université, Faculté de Médecine, Assistance Publique-Hôpitaux de Paris, Paris, France.
Objectives: To investigate factors associated with dermatomyositis (DM) complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM.
Methods: We performed a multicentre, retrospective cohort study. Multivariable survival analyses used a Cox model with time-dependent covariates and adjustments with inverse probability censoring weighting.
[Atypical and/or systemic dermatologic disorders related to immune checkpoint inhibitors: A review].
Rev Med Interne
November 2024
Service de médecine interne et immuno-pathologie, IUCT - Oncopôle, CHU de Toulouse, 1, avenue Joliot-Curie, 31100 Toulouse, France.
Article Synopsis
- Immunological checkpoint inhibitors, used in treating various cancers, can cause toxic side effects, particularly dermatological disorders.
- Common skin issues like maculopapular erythema and pruritus often occur, but rarer conditions such as fasciitis and scleroderma can also arise.
- Recognizing these unusual manifestations is crucial for internists, as they may mimic other diseases or paraneoplastic syndromes, requiring specific diagnostic and treatment approaches related to ICI toxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!